表紙
市場調查報告書

神經性乙醯膽鹼受體次單元Alpha4 (CHRNA4):開發中產品分析

Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 520779
出版日期 內容資訊 英文 59 Pages
訂單完成後即時交付
價格
神經性乙醯膽鹼受體次單元Alpha4 (CHRNA4):開發中產品分析 Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 59 Pages
簡介

本報告提供以神經性乙醯膽鹼受體次單元Alpha4 (CHRNA4)為標的之治療藥開發平台現狀及最新更新之各開發階段比較分析,提供涵括了最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

神經性乙醯膽鹼受體次單元Alpha4 (CHRNA4);概要

神經性乙醯膽鹼受體次單元Alpha4 (CHRNA4);治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀
  • 企業開發中的產品
  • 大學/研究機關開發中的產品

治療藥的評估

  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Catalyst Biosciences Inc
  • H. Lundbeck A/S
  • NeuroDerm Ltd
  • Saniona AB
  • Sopharma AD
  • Suven Life Sciences Ltd

藥物簡介

暫停中的產品

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC2134TDB

Summary

According to the recently published report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019'; Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) pipeline Target constitutes close to 9 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Neuronal acetylcholine receptor subunit alpha 4 or nAChRa4 is a protein encoded by the CHRNA4 gene. It plays a role in fast signal transmission at synapses. Receptors after binding of acetylcholine extensive change conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeable to sodium ions.

The report 'Neuronal Acetylcholine Receptor Subunit Alpha 4 - Pipeline Review, H2 2019' outlays comprehensive information on the Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 3, 2 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Smoking Cessation, Psychiatric Disorders, Alcohol Addiction, Major Depressive Disorder, Neurology and Nicotine Addiction.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
  • The report reviews Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Overview
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Development
  • Products under Development by Stage of Development
  • Products under Development by Therapy Area
  • Products under Development by Indication
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Therapeutics Assessment
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Companies Involved in Therapeutics Development
  • Assuage Pharmaceuticals Inc
  • H. Lundbeck AS
  • Jeil Pharmaceutical Co Ltd
  • Kyung Dong Co Ltd
  • Sopharma AD
  • Suven Life Sciences Ltd
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Drug Profiles
  • AP-202 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • cytisinicline - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • JLP-1603 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • KD-8001 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecule to Antagonize CHRNB2 and CHRNA4 for Psychiatric Disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize CHRNA4 and CHRNB2 for Neurological and Psychiatric disorders - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Antagonize CHRNB2 and CHRNA4 for Smoking Cessation - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • SUVN-911 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varenicline tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • varenicline tartrate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Dormant Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Discontinued Products
  • Neuronal Acetylcholine Receptor Subunit Alpha 4 (CHRNA4) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 09, 2019: Achieve Life Sciences announces completion of meeting with the U.S. Food & Drug Administration (FDA) on Cytisinicline smoking cessation phase 3 clinical development program
  • Oct 24, 2019: Achieve Life Sciences announces presentation of Cytisinicline data at Society for Research on Nicotine & Tobacco Oceania (SRNT-O) Inaugural Conference
  • Sep 30, 2019: Achieve Life Sciences announces completion of maximum tolerated dose study
  • Sep 13, 2019: Achieve Life Sciences announces final phase 2b ORCA-1 trial data presented at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
  • Sep 05, 2019: Achieve Life Sciences to host investor day on September 20th including roundtable discussion with smoking cessation medical experts and final data from the phase 2b ORCA-1trial
  • Jul 23, 2019: Achieve Life Sciences extends collaboration with the National Institutes of Health to advance the development of Cytisinicline for Smoking Cessation
  • Jun 21, 2019: Achieve Life Sciences announces Phase 2b ORCA-1 trial data accepted for oral presentation at Society for Research on Nicotine & Tobacco Europe (SRNT-E) 19th Annual Conference
  • Jun 11, 2019: Achieve Life Sciences announces statistically significant improvement in quit rates for simplified cytisinicline dosing schedule in phase 2b ORCA-1 dose-selection trial
  • May 30, 2019: Achieve announces patent granted in the U.S. for novel formulation of Cytisinicline
  • Apr 24, 2019: Achieve Life Sciences announces last subject, last visit completed in phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
  • Apr 02, 2019: Achieve Life Sciences announces successful completion of the second and final DSMC review of phase 2b ORCA-1 trial of Cytisinicline for Smoking Cessation
  • Feb 22, 2019: FDA updates label for Chantix with data underscoring it's not effective in children 16 and younger
  • Feb 22, 2019: Achieve announces final data from Cytisinicline phase I/II multi-dose, pharmacokinetic and pharmacodynamics (pk/pd) clinical study to be presented at Society for Research on Nicotine & Tobacco Annual Meeting
  • Feb 20, 2019: Achieve Life Sciences announces completion of enrollment in 254-subject phase 2b trial of Cytisinicline for smoking cessation
  • Dec 18, 2018: Achieve Announces Update on Cytisinicline Clinical Development Program
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Therapy Areas, H2 2019
  • Number of Products under Development by Indication, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019
  • Number of Products under Investigation by Universities/Institutes, H2 2019
  • Products under Investigation by Universities/Institutes, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Pipeline by Assuage Pharmaceuticals Inc, H2 2019
  • Pipeline by H. Lundbeck AS, H2 2019
  • Pipeline by Jeil Pharmaceutical Co Ltd, H2 2019
  • Pipeline by Kyung Dong Co Ltd, H2 2019
  • Pipeline by Sopharma AD, H2 2019
  • Pipeline by Suven Life Sciences Ltd, H2 2019
  • Dormant Products, H2 2019
  • Dormant Products, H2 2019 (Contd..1), H2 2019
  • Discontinued Products, H2 2019

List of Figures

  • Number of Products under Development by Stage of Development, H2 2019
  • Number of Products under Development by Indications, H2 2019
  • Number of Products by Mechanism of Actions, H2 2019
  • Number of Products by Stage and Mechanism of Actions, H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019